Biocon Biologics receives Health Canada approval for Yesafili, the first Eylea biosimilar in Canada, with launch slated for ...

Biocon Biologics receives Health Canada approval for its biosimilar Yesafili injection, used to treat various eye ailments.

TORONTO, Ontario, Canada and BENGALURU, Karnataka, India, June 27, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd. (BBL), a ...

Biocon Biologics secures Health Canada approval for Yesafili, the first biosimilar to Eylea® in Canada, with a global launch ...

Bengaluru: Biocon Biologics Ltd ., a fully integrated global biosimilars company and a subsidiary of Biocon Ltd ., has ...

CHENNAI: Biocon Biologics, the biosimilars subsidiary of Biocon Ltd, said on Friday that Health Canada has granted a Notice ...

Biocon said that its subsidiary Biocon Biologics has received a notice of compliance (NOC) for Yesafili (aflibercept), a biosimilar to Eylea (aflibercept) injection, in vial and prefilled syringe ...

Indian drugmaker Biocon has announced that Health Canada has granted a Notice of Compliance for Yesafili (aflibercept), a ...

An EMA committee has recommended approval of Alvotech’s AVT06, a biosimilar to Bayer’s blockbuster ophthalmology drug Eylea.